Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results